COVID-19：FDA 紧急授予“Actemra”：降低死亡率
-类风湿关节炎药物作为新冠治疗药物出现-
FDA = 食品和药物管理局：
感染了新型冠状病毒，
作为住院患者的治疗药物
中外制药研发的类风湿关节炎药物获批紧急使用。
类风湿关节炎药物的紧急使用：
FDA 已批准紧急使用“Actemra”，一种治疗类风湿性关节炎的药物。
中外：
它是由大阪大学岸本忠光教授的一群特聘教授共同开发的。
对于住院病人：
感染了新型冠状病毒，
需要治疗，例如呼吸器，
用于接受甾体抗炎药的住院患者。
降低死亡率的效果：
在 4 项临床试验中
降低住院病人的死亡率，
具有缩短住院时间的效果。
Actemra具有抑制炎症的功能。
它在世界范围内被批准用于治疗类风湿性关节炎。
TBS新闻
https://news.tbs.co.jp/newseye/tbs_newseye4300835.html
Roche’s Actemra gets U.S. FDA approval for hospitalized COVID-19 patients
(Reuters)
The U.S. Food and Drug Administration
issued an emergency use authorization (EUA) for the drug Actemra for the treatment of hospitalized COVID-19 adults and pediatric patients,
the health agency said on Thursday.
The EUA was issued to Genentech, a subsidiary of Roche Holding AG.
The drug can be used to treat patients who are receiving systemic corticosteroids
and
require supplemental oxygen,
non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation,FDA said.
In the clinical trials,
Actemra was shown to reduce the risk of death and time taken to recover by hospitalised patients,the FDA added.
Article [AMP] | Reuters
https://jp.reuters.com/article/health-coronavirus-fda-actemra-idCNL3N2O64HV